What is ADMA's P/E ratio?

ADMA BIOLOGICS INC (ADMA) currently trades at a P/E ratio of 12.15.

ADMA BIOLOGICS INC reports a Return on Equity (ROE) of 42.36%.

What is ADMA's dividend yield?

ADMA BIOLOGICS INC offers a dividend yield of 0.00%.

What is ADMA's Quality Score?

Our AI rates ADMA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ADMA?

Our AI Timing Score for ADMA is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ADMA belong to?

ADMA BIOLOGICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

ADMA (NASDAQ) Stock Analysis | ADMA BIOLOGICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ADMA AI Analysis Summary

Our AI summary for ADMA: ADMA BIOLOGICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 12.15, ROE of 42.36%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ADMA

ADMA BIOLOGICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 81

USD 8.46

-0.21 (-2.42%) Day Change

Watchlist Portfolio Compare Chart

12.15

P/E

0.51

D/E

42.4%

ROE

24.9%

ROA

0.00%

Div Yield

-0.04

PEG

ADMA BIOLOGICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 8.46 Price -0.21 (-2.42%) Day Change	NEWS SCORE: 81

ADMA, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...

Quality Factors

52%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	81
Magic Formula Rank by ROA	241
Magic Formula Rank by ROE	241
Magic Formula Rank by ROIC	227
Price	8.46
PBV / Sector	5.15 / 5.20
Earning Per Share	0.70

PE / Sector	12.15 / 19.97 GOOD
PEG or PE/Growth / Sector	-0.04 / 1.22
Average 1M Daily Value	21.23 M GREAT
Average 1W Daily Value	16.05 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	32.43 / 98.71 GREAT
NPM Average (%) / Sector	10.78 / -1,721.76 GOOD
NPM Change Average (%) / Sector	-155.88 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	24.86 / 27.02 GOOD
ROA Average (%) / Sector	12.27 / -368.17
ROA Change Average (%) / Sector	-165.59 / 5,404.12
ROE (%) / Sector	42.36 / 3.47 GREAT
ROE Average (%) / Sector	13.11 / 6.51
ROE Change Average (%) / Sector	-107.76 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:26
Symbol	ADMA
Name	ADMA BIOLOGICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	231.77 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,009.47 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 465 State Route 17, Ramsey, NJ, United States, 07446

Phone: 201 478 5552

Website: https://www.admabiologics.com

Employees: 640

Sector: Healthcare >> Biotechnology

Description: ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.